Your browser doesn't support javascript.
loading
Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia.
Werner, Benjamin; Gallagher, Robert E; Paietta, Elisabeth M; Litzow, Mark R; Tallman, Martin S; Wiernik, Peter H; Slack, James L; Willman, Cheryl L; Sun, Zhuoxin; Traulsen, Arne; Dingli, David.
Afiliação
  • Werner B; Department of Evolutionary Theory, Max Planck Institute for Evolutionary Biology, Plön, Germany.
  • Gallagher RE; Montefiore Medical Center, Bronx, New York, New York.
  • Paietta EM; Montefiore Medical Center, Bronx, New York, New York.
  • Litzow MR; Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
  • Tallman MS; Northwestern University, Chicago, Illinois.
  • Wiernik PH; Beth Israel Medical Center, New York, New York.
  • Slack JL; Division of Hematology, Mayo Clinic Arizona, Scottsdale, Arizona.
  • Willman CL; University of New Mexico Cancer Center, Albuquerque, New Mexico.
  • Sun Z; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts.
  • Traulsen A; Department of Evolutionary Theory, Max Planck Institute for Evolutionary Biology, Plön, Germany.
  • Dingli D; Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota. dingli.david@mayo.edu.
Cancer Res ; 74(19): 5386-96, 2014 Oct 01.
Article em En | MEDLINE | ID: mdl-25082816
Many tumors are believed to be maintained by a small number of cancer stem-like cells, where cure is thought to require eradication of this cell population. In this study, we investigated the dynamics of acute promyelocytic leukemia (APL) before and during therapy with regard to disease initiation, progression, and therapeutic response. This investigation used a mathematical model of hematopoiesis and a dataset derived from the North American Intergroup Study INT0129. The known phenotypic constraints of APL could be explained by a combination of differentiation blockade of PML-RARα-positive cells and suppression of normal hematopoiesis. All-trans retinoic acid (ATRA) neutralizes the differentiation block and decreases the proliferation rate of leukemic stem cells in vivo. Prolonged ATRA treatment after chemotherapy can cure patients with APL by eliminating the stem-like cell population over the course of approximately one year. To our knowledge, this study offers the first estimate of the average duration of therapy that is required to eliminate stem-like cancer cells from a human tumor, with the potential for the refinement of treatment strategies to better manage human malignancy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Leucemia Promielocítica Aguda Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Leucemia Promielocítica Aguda Idioma: En Ano de publicação: 2014 Tipo de documento: Article